People

Neuromyelitis Optica, Part 2: Pathogenesis

Now that we’ve seen how researchers came to the conclusion that NMO differs from MS, let’s take a closer look at the current understanding of its pathogenesis

About three-quarters of NMO patients have the aquaporin-4 antibody, a number that has been steadily...

Clinical Research, Drug Development, Laboratory Research, People

Neuromyelitis Optica, Part 1: The Other Disease

Once thought of as a variant of multiple sclerosis, neuromyelitis optica is now clearly understood to be a different disease

Lea Long still remembers the moment her life changed like it was yesterday. She was in the...

Clinical Research, Drug Development, Laboratory Research, People

Debate: Do Physicians Rate the Risk of Disabling MS Less Than the Risk of Effective Treatment?

MS prescribing depends on balancing benefit against hard-to-assess risk. At the recent World Congress of Neurology in Vienna, two experts in MS debated whether physicians rate the risk of disabling MS less than the risk of effective treatment. The debate centered on how clinicians and patients perceive risk and how decision-making must be done collaboratively.

How much risk is appropriate in the treatment of multiple sclerosis? For that matter, which risks should we focus on...

People

Survey Finds “MSer” to Be Patients' Preferred Descriptor

A convenience survey of people with MS found "MSer" to be the preferred descriptor for a person with the disease

What is the preferred way for clinicians and researchers to refer to people who...

People

Nominations Open for Dystel Prize for MS Research

Deadline: October 30, 2013

The John Dystel Prize for Multiple Sclerosis Research is awarded jointly by the National Multiple Sclerosis Society and the American Academy of Neurology (AAN).

Clinical Research, Drug Development, Laboratory Research, Meetings, Methods, People